Biogen Q3 top line up 6%; non-GAAP EPS up 16%; shares ahead 3% premarket

• Biogen (NASDAQ:BIIB) Q3 results ($M): Total Revenues: 2,955.8 (+6.4%); Product Sales: 2,539.6 (+6.2%); Joint Business: 317.6 (-5.8%).
• Net Income: 1,032.9 (+7.0%); Non-GAAP Net Income: 1,137.7 (+9.2%); EPS: 4.71 (+13.5%); Non-GAAP EPS: 5.19 (+15.8%).
• Key Product Sales: Tecfidera: 1,033.7 (+4.1%); Total Interferon: 708.3 (+3.4%); Tysabri: 515.5 (+3.6%); Eloctate: 131.8 (+45.5%); Alprolix: 85.2 (+29.7%).